Timeline
Ondine Biomedical
Ondine pushes back Phase 3 nasal infection study readout
Market Brief: easyJet rejects Castlelake takeover bids, BATM Advanced Communications, Ondine Biomedical, Babcock International, Synthomer
Ondine Biomedical expects Phase 3 top-line results within three weeks
Ondine Biomedical nasal photodisinfection cuts brain surgery infections by 78.5%
Ondine Biomedical reports ICU feasibility study with signals of reduced pneumonia
Ondine Biomedical raises £5m at 12p to fund NDA preparation
Ondine study shows 39.5% cut in ICU pneumonia and is accepted for CACCN oral presentation
Ondine Biomedical (AIM:OBI) shares surged 7.4% after Ottawa Heart Institute study
Ondine Biomedical to showcase at World Congress on Infectious Diseases
Ondine-backed ICU pilot cuts pneumonia by 39.5% with five-minute nasal treatment
Ondine boosted by patient enrolment, revenues rise and factory upgrades begin
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.